PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+15.6% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$17M-636.2% margin

Net Income

-$18M-643.7% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-34.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$155M

Total Liabilities

$75M

Stockholders' Equity

$80M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+15.6%
Gross Profit	$3M	$2M	+15.6%
Operating Income	-$17M	-$15M	-12.2%
Net Income	-$18M	-$14M	-26.2%

PTGX Q4 2019 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena